Sabin株灭活脊灰疫苗在婴儿中的免疫原性与安全性:系统综述与荟萃分析
该系统综述与荟萃分析纳入7项随机对照试验、共4646名健康婴儿,比较Sabin株灭活脊灰疫苗(sIPV)与常规Salk株灭活脊灰疫苗(cIPV)完成基础免疫程序后的免疫原性与安全性。结果显示,sIPV的血清阳转率与cIPV相当,PV1与PV2的几何平均滴度(GMT)更高;局部不良事件相似,cIPV的全身不良事件更多,而sIPV的发热与过敏反应略多。sIPV免疫原性可比且安全性可接受,其较低的生物安全要求支持在全球消灭脊灰规划中使用。
要点
- sIPV血清阳转率与cIPV相当,PV1、PV2的GMT更高
- 局部不良事件两组相似,cIPV全身不良事件更多
- sIPV发热与过敏反应略多,总体安全性可接受
核心结论
- 在完成基础IPV程序的健康婴儿中,sIPV免疫原性与cIPV相当且安全性可接受,较低的生物安全要求支持其用于全球消灭脊灰规划。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase、Scopus和Cochrane Library的随机对照试验,纳入7项RCT共4646名婴儿。
- 采用随机效应模型合并数据,使用RoB 2.0评估偏倚风险、GRADE评估证据确定性。
主要发现
- 血清阳转率PV1为100%(RR 1.00,95%CI 1.00-1.01),PV2为102%(RR 1.02,95%CI 0.98-1.07),PV3为100%(RR 1.00,95%CI 0.99-1.01)。
- sIPV的GMT在PV1后更高(MD 1.50,95%CI 0.98-2.02),PV2后亦更高(MD 0.52,95%CI 0.06-0.98)。
- 局部不良事件两组相似(OR 1.27,95%CI 0.95-1.71),cIPV的全身不良事件更多(OR 1.36,95%CI 1.15-1.60)。
- sIPV的发热(OR 1.50,95%CI 1.20-1.87)与过敏反应(OR 2.19,95%CI 1.02-4.69)略多。
关键数值与推荐
- 血清阳转率比较:PV1 RR 1.00(95%CI 1.00-1.01)、PV2 RR 1.02(95%CI 0.98-1.07)、PV3 RR 1.00(95%CI 0.99-1.01)。
- GMT比较:PV1 MD 1.50(95%CI 0.98-2.02),PV2 MD 0.52(95%CI 0.06-0.98)。
- 不良事件:局部OR 1.27(95%CI 0.95-1.71);全身OR 1.36(95%CI 1.15-1.60);发热OR 1.50(95%CI 1.20-1.87);过敏反应OR 2.19(95%CI 1.02-4.69)。
临床怎么用
- sIPV可作为婴儿基础IPV程序的替代选择,其免疫原性与cIPV相当且生物安全要求更低。
- 接种sIPV时需关注发热与过敏反应,接种cIPV时需关注全身不良事件。
局限性
- 纳入研究数量有限(7项RCT),证据确定性经GRADE评估,具体降级情况原文未详述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Poliomyelitis remains a threat to children under five despite global vaccination efforts. The Sabin-strain inactivated poliovirus vaccine (sIPV) has emerged as a safer alternative to conventional Salk-strain IPV (cIPV) due to lower biosafety requirements. This systematic review and meta-analysis evaluated the immunogenicity and safety of sIPV compared with cIPV in healthy infants completing the primary IPV series. METHODS: PubMed, Embase, Scopus, and Cochrane Library were searched for RCTs. Outcomes included seroconversion rates, seroprotection rates, geometric mean titers (GMTs), and adverse events. Data were pooled using random-effects models, and evidence certainty was assessed using RoB 2.0 and GRADE. RESULTS: Seven RCTs with 4646 infants were included. Seroconversion rates were comparable: PV1 100% (RR 1.00, 95% CI 1.00-1.01), PV2 102% (RR 1.02, 95% CI 0.98-1.07), PV3 100% (RR 1.00, 95% CI 0.99-1.01). GMTs were higher for sIPV after PV1 (MD 1.50, 95% CI 0.98-2.02) and PV2 (MD 0.52, 95% CI 0.06-0.98). Local adverse events were similar (OR 1.27, 95% CI 0.95-1.71), while systemic adverse events were higher with cIPV (OR 1.36, 95% CI 1.15-1.60). Fever (OR 1.50, 95% CI 1.20-1.87) and allergic reactions (OR 2.19, 95% CI 1.02-4.69) were slightly more frequent with sIPV. CONCLUSIONS: sIPV provides immunogenicity comparable to cIPV with an acceptable safety profile in infants. Its lower biosafety requirements support its use in global polio eradication programs.
引用
- Hussain M, Hassan M, Athar M, et al. Immunogenicity and safety of Sabin-strain inactivated poliovirus vaccine in infants: a systematic review and meta-analysis. Vaccine. 2026. PMID: 42060979. doi:10.1016/j.vaccine.2026.128643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。